An antibody-lectin sandwich assay for the determination of CA125 antigen in ovarian cancer patients

Liquid Crystal Biosensors: A New Therapeutic Window to Point-of-Care Diagnostics

After revolutionizing the field of electro-optic displays, liquid crystals (LCs) are emerging as functional soft materials with wide-ranging biomedical implications. Integrating smart sensor designs with label-free imaging presents exciting opportunities in diagnostics. In this Perspective, we present an elegant collage of the key findings that demonstrate the utility of LC biosensors in diagnosing a disease or infection in clinical samples, cellular microenvironments, or bodily fluids. We emphasize the currently prevalent diagnostic techniques and the advances made using LCs in achieving greater sensitivity, a simplified strategy, multiplexed detection, and so on. We collate the landmark contributions in translational research in LC-based diagnostics. We believe that developing LC-based biosensors presents a new therapeutic window in point-of-care diagnostics.

Lectin biosensors in cancer glycan biomarker detection

Cancer has high incidence and it will continue to increase over the next decades. Detection and quantification of cancer-associated biomarkers is frequently carried out for diagnosis, prognosis and treatment monitoring at various disease stages. It is well-known that glycosylation profiles change significantly during oncogenesis. Aberrant glycans produced during tumorigenesis are, therefore, valuable molecules for detection and characterization of cancer, and for therapeutic design and monitoring. Although glycoproteomics has benefited from the development of analytical tools such as high performance liquid chromatography, two-dimensional gel and capillary electrophoresis and mass spectrometry, these approaches are not well suited for rapid point-of-care (POC) testing easily performed by medical staff. Lectins are biomolecules found in nature with specific affinities toward particular glycan structures and bind them thus forming a relatively strong complex. Because of this characteristic, lectins have been used in analytical techniques for the selective capture or separation of certain glycans in complex samples, namely, in lectin affinity chromatography, or to characterize glycosylation profiles in diverse clinical situations, using lectin microarrays. Lectin-based biosensors have been developed for the detection of specific aberrant and cancer-associated glycostructures to aid diagnosis, prognosis and treatment assessment of these patients. The attractive features of biosensors, such as portability and simple use make them highly suitable for POC testing. Recent developments in lectin biosensors, as well as their potential and pitfalls in cancer glycan biomarker detection, are presented in this chapter.

Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera

Elevated serum CA15-3 assessed by enzyme-linked immunosorbent assay (ELISA) has been considered a diagnostic marker of breast cancer. However, accumulating data indicate that the current ELISA system for detecting CA15-3, which targets the peptide backbone of CA15-3, is not sufficiently sensitive to detect early or localized breast cancer. In the present study, we designed an antibody-lectin sandwich assay detecting glycosylation of CA15-3 in patients with breast cancer. Immobilized anti-CA15-3 monoclonal antibody captures CA15-3 in serum, and glycosylation of the CA15-3 is detected with Concanavalin A (ConA) lectin, which preferentially bind high-mannose N-glycans. ConA provided the best signal for detecting serum CA15-3 among 9 types of lectin, Since CA15-3 is a heavily glycosylated protein, detecting the glycosylation of CA15-3 should be a much more sensitive way to assess CA15-3 than the current ELISA method. Linear responses were obtained in the anti-CA15-3 antibody-ConA sandwich assay when sera were diluted up to 2000-fold. This dilution factor is comparable with that of the current ELISA system which allows 50- to 100-fold serum dilutions. The glycosylation level of CA15-3 was found to increase with increasing breast cancer stage in the sandwich assay. The assay system appeared to efficiently discriminate breast cancer stage I (sensitivity: 63%, specificity: 69%), IIA (sensitivity: 77%, specificity: 75%), IIB (sensitivity: 69%, specificity: 86%) and III (sensitivity: 80%, specificity: 65%) from benign breast disease. The antibody-lectin sandwich assay shows promise as a new prospect for the early detection of breast cancer.

Immunoassays for the cancer biomarker CA125 based on a large-birefringence nematic liquid-crystal mixture

The use of fluorescence is ubiquitously found in the detection of immunoreaction; though with good sensitivity, this technique requires labeling as well as other time-consuming steps to perform the measurement. An alternative approach involving liquid crystals (LCs) was proposed, based on the fact that an immunocomplex can disturb the orientation of LCs, leading to an optical texture different from the case when only antigen or antibody exists. This method is label-free, easy to manipulate and low-cost. However, its sensitivity was low for practical usage. In this study, we adopted a high-birefringence liquid crystal (LC) to enhance the sensitivity for the immunodetection. Experiments were performed, targeting at the cancer biomarker CA125. We showed that the larger birefringence (Δn = 0.33 at 20 °C) amplifies the detected signal and, in turn, dramatically improves the detection limit. To avoid signal loss from conventional rinsing steps in immunodetection, CA125 antigen and antibody were reacted before immobilized on substrates. We studied the specific binding events and obtained a detection limit as low as 1 ng/ml. The valid temperature ranges were compared by using the typical single-compound LC 5CB and the high-birefringence LC mixture. We further investigated time dependency of the optical textures and affirmed the capability of LC-based immunodetection in distinguishing between specific and nonspecific antibodies.

A simple and reliable method for the detection of sialylation in complex/hybrid-type carbohydrate chains of glycoproteins by mixed lectins

A practical and convenient method for discriminating between the presence and the absence of sialic acid in carbohydrate chains of glycoproteins was devised using paramagnetic beads and two lectins, Sambucus sieboldiana lectin (SSA) and Ricinus communis agglutinin (RCA120). The glycoproteins of transferrin or thyroglobulin were firstly captured to paramagnetic beads that were previously coated with corresponding antibody, and then the lectins of RCA120-biotin and SSA-FITC were bound to the glycoproteins on the paramagnetic beads. Finally, the fluorescence intensity of the beads was measured to determine the ratios of lectins RCA120-biotin/Cy5-streptavidin to SSA-FITC. The mixed lectins method showed bigger difference of the ratios between the presence and the absence of sialic acid, indicating higher discrimination efficiency than the ordinary non-mixed lectins method. Furthermore, statistical analysis by two-side t-test indicated that the mixed lectins method was more highly reliable than the ordinary non-mixed lectins method in discriminating between the presence and the absence of sialic acid. The reaction with the two lectins can be performed in a single tube and readily automated taking advantage of the use of paramagnetic beads.

Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancy-associated CA125 antigen

BACKGROUND

The cancer antigen CA125 has a very complex molecular architecture in terms of both protein backbone and oligosaccharide chains. In this study, we examined the molecular forms and microheterogeneity of oligosaccharide chains of pregnancy-associated CA125, as a first step towards gaining an insight into its possible involvement as a ligand in carbohydrate-dependent interactions. The glycobiochemical properties of CA125 may be of diagnostic and biomedical importance as specific markers of physiological and pathological conditions of early pregnancy, as well as targets in different therapeutic procedures.

METHODS

Pregnancy-associated CA125 was characterized by gel filtration and ion-exchange chromatography, followed by lectin-affinity chromatography with a panel of plant lectins as ligands.

RESULTS

CA125 antigen isolated from first trimester placental extract was found to be heterogeneous in respect to molecular mass and the existence of different glyco-isoforms. Thus, elution profiles from the lectin-affinity columns demonstrated molecular subpopulations bound with low, intermediate and high affinity. Under the applied experimental conditions, CA125 bound most strongly to Triticum vulgaris agglutinin (WGA) and Ricinus communis agglutinin (RCA), but low affinity interactions occurred with the other lectins tested.

CONCLUSIONS

The assessment of the carbohydrate composition of N- and O-glycans of pregnancy-associated CA125 was in general agreement with available data on CA125 of cancer origin. The main difference was observed in reactivity to Canavalia ensiformis agglutinin (ConA) and Phaseolus vulgaris erythroagglutinin (PHA-E) binding.

The development of a sialic acid specific lectin-immunoassay for the measurement of human chorionic gonadotrophin glycoforms in serum and its application in normal and Down's syndrome pregnancies

OBJECTIVE

We have developed and validated a lectin-immunoassay for the recognition of sialic acid residues on hCG glycoforms in serum.

DESIGN

This assay employs a hCG specific capture antibody and a sialic acid specific lectin (Wheat Germ Agglutinin) labelled with horse radish peroxidase.

RESULTS

The standard curve covered hCG concentrations of 0-4000 IU/l (3rd IS for hCG, 75/537) with an analytical sensitivity of 1.0 IU/l. The within and between batch coefficient of variation was < 7% for all doses. Cross-reactivity of < 1% with TSH, LH, FSH, hCGalpha, hCGbeta and desialylated hCG confirmed assay specificity. Dilutions of serum of < 10% final concentration were parallel to the standard curve (within and between batch CV, < 6%). The assay working range was 100 - > 500 000 IU/l and the recovery of hCG from serum was in the range of 94.5% to 115.4%, with a mean value of 102.1%. The assay detected a time dependent change in hCG sialylation during normal pregnancy with the relative abundance of sialylated hCG declining after week 9 and increasing after week 15 of gestation. In addition preliminary studies showed that maternal serum hCG concentrations measured with the lectin-immunoassay were elevated in high risk Down's pregnancies (as defined by conventional screening tests between weeks 16-18 gestation, median multiple of median, 3.14; range 1.81-19.12, P < 0. 001) and low risk (1.57, 0.49-6.14, P = 0.034) compared to normal (1. 00, 0.32-3.20) pregnancies. Furthermore, the lectin immunoassay had greater discriminatory power compared to conventional immunoassay of hCG and hCGbeta between normal and both low and high risk Down's pregnancies.

CONCLUSION

This assay will allow analysis of serum samples for the investigation of sialylated variants of hCG glycoforms in various pathological and physiological situations.